Suzhou Teligene Ltd.

This Phase 2 trial is testing whether a new drug called TL938, taken as a pill, combined with the targeted therapy trastuzumab (given by IV), can shrink tumors in people with HER2-positive colorectal cancer that has spread or come back. The study will enroll 80 adults who have al…